In this article, we will discuss some of the basic regulatory steps for obtaining reimbursement-approval for medical devices, and list the key impacts and strategic considerations when dealing with HC reimbursement in China.
Home > Archives for Helgert Van Raamt
Author: Helgert Van Raamt
About Helgert Van Raamt
Posts by Helgert Van Raamt:
It has been told sufficiently that the old way of launching and selling a product is no longer the standard approach. Physicians are no longer the deciding factor, at least not in most of the European countries. In a country like Germany, physicians and surgeons still have influence in some situations, in the sense of […]
It wasn’t even that long ago that the world of the MedTech market was relatively simple to read. Recognizable competitive challenges, evolutionary developments; a world that we were familiar with and were able to map the developments of for 5 years at a time -and when accepting a certain margin of uncertainty- possibly forecast even […]
Shifts in Patient Care: Strategizing for Reimbursement Claims and the Positioning of Medical Devices
It seems that the rapid structural changes in the medical device market amongst providers are creating a momentum that we have not seen in the past – or at least not since a long time. In this blog we are looking at two changes that have an influence on the market in the short term, […]
The Market for Medical Devices in Latin America: Leaving the years of unpredictability far behind, and growing steadily into an opportunity to build a stable business
It is already a number of years ago that we started wondering when countries like Brazil, Mexico, Colombia and Argentina would finally leave their status of “promising” behind them, and develop into predictable, flourishing healthcare markets that would allow sustainable commercial operations. With a bit of candor, Latin America is developing into that sizable, predictable […]
The last five to ten years have substantially changed the essential elements, deciding on process and outcome of marketing processes, the marketing landscape. Not too long ago, the launch of (new) products or technologies went along simple and understandable lines. TforG has watched how these changes have quickly affected the medical devices industry.
The global medical device markets will reach approx. $380 bln in the year to come and the Middle East will contribute a mere $ 3.5 bln, e.g. less than 1 % to that total. Even in the “newly applied” definition of Middle East, including North Africa (MENA) but excluding Turkey in the west and Pakistan […]
In two previous articles we have described and commented on two major influences on today’s Medical Device market in Europe. In this blog article, Helgert Van Raamt reflects upon the impact of regulation and new economical realities on medical devices innovation and pricing.
DRG’s and their effect on Medical Device Introduction, Reimbursement and the increasing medical professional resistance to new devices. This is the first blog in the series that identifies and discusses new obstacles in the marketing of Medical Devices, new hurdles, shifting roles and changing weights.
……and should solve major quality and safety issues. Every time there is a public health scandal of some substance, the authorities respond with an overhaul of the relevant regulations. This was the case after the PIP (Poly Implant Prothèse) breast implant scandal.